Celltrion's Steqeyma (Biosimilar, Stelara) Adds into the Costco Member Prescription Program
Shots:
- Celltrion announced that Steqeyma (ustekinumab-stba), a biosimilar to Stelara, has been added to the Costco Member Prescription Program. It was launched on Mar 12, 2025. Celltrion's adalimumab-aaty was added to the program in Aug 2024
- Steqeyma will be available in the US from Costco Specialty Pharmacies on Apr 1, 2025, for self-funded employer plans, uninsured Costco members paying cash, or those denied insurance coverage
- Steqeyma, a human IL-12 & IL-23 antagonist, is available as SC injection (45mg/0.5mL or 90mg/1mL in a single-dose, prefilled syringes) & IV infusion (130mg/26mL solution in a single-dose vial) for the treatment of PsO & PsA in adult & pediatric patients, as well as for CD and UC adult patients
Ref: Prnewswire | Image: Celltrion
Related News:- Celltrion launches SteQeyma (Biosimilar, Stelara) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
